Date: 2013-03-13
Type of information: Collaboration agreement
Compound: SistemQC™ stem cell characterisation technology
Company: Sistemic (UK) Progenitor Cell Therapy (USA)
Therapeutic area:
Type agreement: collaboration
services
Action mechanism:
Disease:
Details: * On March 13, 2013, Sistemic Limited, a miRNA profiling company with facilities in Glasgow, Scotland and Boston, has announced the signature of an agreement to allow Progenitor Cell Therapy (PCT), a CDMO in the cellular therapy industry and a subsidiary of NeoStem, to initiate evaluation studies on Sistemic’s SistemQC™ stem cell characterisation technology.
The studies have been designed to allow PCT to evaluate the applicability of SistemQC™ technology in stem cell characterisation employing Sistemic’s patented miRNA profiling system and proprietary analytical approaches to produce miRNA panels, termed Key miRNAs or KmiRs™, which PCT may look to employ in the future in process optimisation and cell characterisation.
Financial terms:
Latest news:
